PDCD7

Across TCGA pan-cancer cohorts, PDCD7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDCD7 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDCD7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

PDAC, HNSC, and GBM are the cancer types where PDCD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.706	0.871	.024	15	view →
HNSC	DFS	Median	III,IV	0.895	0.300	.005	7	view →
GBM	DFS	Tertile	All	0.819	0.717	.048	3	view →
LSCC	DFS	Median	II,III,IV	0.808	0.561	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDCD7–PDAC (OS)

Open the PDAC breakdown →